MTHFR rs33972313: Understanding the Rare p.Arg157Gln Variant
The rs33972313 variant is a rare missense change in the MTHFR gene, resulting in the substitution of glutamine for arginine at amino acid position 157 (p.Arg157Gln). Research identifies it as a functional alteration that can diminish methylenetetrahydrofolate reductase enzyme activity. It has been primarily investigated in relation to folate metabolism and elevated circulating homocysteine levels (hyperhomocysteinemia).
What each genotype means
Typical enzyme activity
This is the most common genotype for this variant. It is associated with standard MTHFR enzyme function as observed in the general population.
This is the predominant genotype found in the vast majority of the global population.
Reduced enzyme activity
This genotype represents a heterozygous state for a rare missense variant. Research suggests this may be associated with reduced MTHFR enzyme activity and potentially higher homocysteine levels, though the clinical significance remains limited.
This genotype is rare, occurring in less than 0.1% of most global populations.
Significantly reduced enzyme activity
This genotype is homozygous for a rare variant associated with reduced folate pathway enzyme activity. While linked to hyperhomocysteinemia in some studies, the clinical impact is not fully established and should be discussed with a healthcare provider.
This genotype is extremely rare, with a frequency significantly below 0.001 in global populations.
Genetic Location and Molecular Characteristics of rs33972313
The single nucleotide polymorphism rs33972313 is located within the human MTHFR gene on chromosome 1. At the nucleotide level, it represents a missense substitution that alters the coding sequence, replacing an arginine residue with a glutamine at position 157 of the protein (annotated as p.Arg157Gln, or historically as Arg134Gln depending on the transcript isoform). Unlike common polymorphisms in this gene, rs33972313 is a rare variation in the general population. Because it modifies an amino acid in a functional region of the enzyme, biochemical studies categorize it as a functional missense allele that can directly alter protein folding or kinetic stability.
The Biological Role of the MTHFR Enzyme
The MTHFR gene provides instructions for producing the methylenetetrahydrofolate reductase enzyme, a foundational regulatory catalyst in one-carbon metabolism. This enzyme converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the predominant circulating form of folate in human blood. This active folate derivative is essential for the remethylation of homocysteine to methionine, a precursor for S-adenosylmethionine (SAMe), which serves as the universal methyl donor for cellular methylation, including DNA and protein modification. Impairments in this pathway can lead to reduced methionine synthesis and an accumulation of homocysteine in the bloodstream.
Clinical Evidence and Association with Hyperhomocysteinemia
Evidence evaluating rs33972313 is classified as limited compared to common polymorphisms. In vitro enzyme assays and clinical genetics studies have demonstrated that the p.Arg157Gln alteration produces a significant reduction in basal MTHFR enzymatic activity. When combined with other pathogenic or functional variants, or in the presence of severe nutritional deficiencies, this functional decrease can contribute to hyperhomocysteinemia. However, because rs33972313 is rare, large-scale genome-wide association studies (GWAS) lack statistical power to definitively quantify its independent disease risks across diverse populations. Current scientific literature views it as a biochemically active allele whose clinical impact depends heavily on overall genotype and nutritional status.
Population Frequency and Distribution
According to large-scale sequencing datasets such as the Genome Aggregation Database (gnomAD), rs33972313 is an uncommon to rare variant, possessing an overall minor allele frequency well below 0.001 (less than 0.1%) globally. Most individuals across all major ancestry groups carry two copies of the reference allele. Heterozygous carriers are rarely identified outside of targeted clinical sequencing, and homozygous individuals are exceptionally rare. Due to its scarcity, population-specific prevalence patterns remain largely uncharacterized in most demographic cohorts.
Navigating Results: What to Do and What to Avoid
Discovering an rs33972313 variant on a comprehensive genetic test should be approached with measured perspective. Genetic markers associated with MTHFR do not act as clinical diagnoses on their own. Health organizations, including the Centers for Disease Control and Prevention (CDC) and major medical societies, emphasize that nutritional intake of essential B-vitamins—such as folate, vitamin B12, and vitamin B6—is typically the dominant factor influencing homocysteine levels. Individuals should never initiate high-dose vitamin regimens or alter prescribed medications without medical oversight. Anyone with questions regarding elevated homocysteine or rare genetic findings should consult a qualified physician or genetic counselor.
How common is this variant?
The rs33972313 variant is rare globally, observed at an allele frequency of less than 0.001 (<0.1%) across ancestral cohorts in the gnomAD database, with the vast majority of individuals being homozygous for the reference allele.
Frequently asked questions
What is the difference between rs33972313 and common MTHFR variants like C677T?
Common variants such as C677T (rs1801133) are carried by a large percentage of the general population and confer modest reductions in enzyme stability. In contrast, rs33972313 is an uncommon missense variant that occurs in fewer than 1 in 1,000 individuals and produces a more distinct reduction in functional enzymatic activity.
Does having an rs33972313 variant mean I have a disease?
No, carrying a single copy of rs33972313 does not equate to a medical diagnosis. It indicates a genetic tendency toward lower enzymatic activity, but actual health outcomes depend heavily on diet, lifestyle, and other genetic factors.
Should I stop taking regular folic acid if I have this variant?
No. Leading public health authorities, including the CDC, clarify that individuals with MTHFR variants can still process dietary folate and folic acid. Any dietary or supplement modifications should be discussed directly with a healthcare provider.
Can routine blood tests check if this variant is affecting my body?
Yes, clinicians frequently evaluate one-carbon metabolism by measuring circulating total homocysteine, serum folate, and vitamin B12 levels. These functional biomarkers provide a clearer immediate picture of metabolic health than genetic testing alone.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs33972313?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MTHFR
Variant in the MTHFR locus frequently studied in association with folate metabolism and homocysteine levels.
MTHFR missense variant (c.1793G>A, p.Arg594Gln) commonly evaluated alongside canonical variants for folate metabolism and hyperhomocysteinemia predisposition.
Functional polymorphism influencing homocysteine dynamics and vascular endothelial recovery during high-intensity training.
Common variant (C677T) influencing folate metabolism and plasma homocysteine levels.
The C677T variant in the MTHFR gene is associated with reduced enzyme activity and mild hyperhomocysteinemia, particularly in individuals with low folate intake.
The MTHFR 677C>T (Ala222Val) variant encodes a thermolabile enzyme with reduced activity. While associated with elevated homocysteine levels in the presence of low folate, major professional guidelines (e.g., ACMG) advise against routine clinical testing for cardiovascular or thrombophilia risk due to lack of clinical utility.